Global Zanidatamab Market Size, Share & Trends Analysis Report By Indication (HER2-Positive Biliary Tract Cancer, HER2-Positive Gastric & Gastroesophageal Junction Cancer, HER2-Positive Breast Cancer, HER2-Positive Colorectal Cancer, Other HER2-Expressing Solid Tumors), By Line of Therapy (First-Line, Second-Line, Third-Line & Beyond), By Combination Regimen (Monotherapy, With Chemotherapy, With Immunotherapy, With Other Targeted Agents), By Distribution Channel (Hospital Pharmacies, Specialty Cancer Centers, Ambulatory Oncology Clinics, Online Pharmacies), and By Region – Forecasts, 2026–2034

Table of Contents

1. Introduction
   1. Introduction
   2. Market Introduction
   3. Research Methodology
   4. Estimation Methodology
   5. Zanidatamab Market Ecosystem Overview
   6. Market Classification & Scope
   7. Geographic Scope
   8. Study Years
2. Market Dynamics
   1. Drivers: Rising Incidence of HER2-Positive Biliary Tract Cancer and Unmet Treatment Need
   2. Drivers: Differentiated Bispecific HER2 Mechanism Overcoming Treatment Resistance
   3. Restraints: Accelerated Approval Dependency and Confirmatory Trial Risks
   4. Restraints: Limited HER2 Testing Rates and Biomarker Identification Challenges
   5. Opportunities: First-Line Combination Therapy Expansion in Gastric and Biliary Tract Cancers
   6. Opportunities: Indication Expansion Across HER2-Expressing Solid Tumors
   7. Trends: Biomarker-Driven Precision Oncology Approaches
   8. Trends: Advanced Companion Diagnostic Development and AI-Assisted HER2 Testing
3. Market Segmentation (2026–2034)
   1. By Indication
      1. HER2-Positive Biliary Tract Cancer
      2. HER2-Positive Gastric & Gastroesophageal Junction Cancer
      3. HER2-Positive Breast Cancer
      4. HER2-Positive Colorectal Cancer
      5. HER2-Mutated Non-Small Cell Lung Cancer
      6. Other HER2-Expressing Solid Tumors
   2. By Line of Therapy
      1. First-Line Therapy
      2. Second-Line Therapy
      3. Third-Line & Beyond
   3. By Combination Regimen
      1. Zanidatamab Monotherapy
      2. Zanidatamab + Chemotherapy
      3. Zanidatamab + Immunotherapy (PD-1/PD-L1 Inhibitors)
      4. Zanidatamab + Other Targeted Agents
      5. Zanidatamab + Triplet Combinations
   4. By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Cancer Centers
      3. Ambulatory Oncology Clinics
      4. Academic Medical Centers
      5. Online/Mail-Order Pharmacies
   5. By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Middle East & Africa
      5. Latin America
4. Regional Overview
   1. North America
   2. Europe
   3. Asia Pacific
   4. Middle East & Africa
   5. Latin America
5. Competitive Analysis
   1. Market Share Analysis
   2. Competitive Benchmarking
   3. Revenue Analysis
   4. Clinical Pipeline Assessment
   5. Product Positioning and Differentiation
   6. Strategic Collaborations and Licensing Agreements
   7. Recent Developments
6. Clinical Development & Innovation Trends
   1. Evolution of Bispecific HER2 Antibody Therapies
   2. First-Line Combination Therapy Development
   3. Expansion into HER2-Low and HER2-Mutated Tumors
   4. Companion Diagnostics and Precision Oncology
   5. AI-Enabled Biomarker Identification
   6. Combination Strategies with Immunotherapy
   7. Next-Generation HER2-Targeted Treatment Approaches
7. Regulatory & Reimbursement Landscape
   1. FDA Accelerated Approval Framework
   2. EMA Regulatory Pathways
   3. Asia Pacific Oncology Approval Landscape
   4. Companion Diagnostic Regulatory Requirements
   5. Pricing and Reimbursement Considerations
   6. Market Access and Payer Assessment Strategies
8. Market Research Findings & Conclusion
9. Disclaimer